SEATTLE and DIJON, France, Feb. 08, 2022 (GLOBE NEWSWIRE) -- SEngine Precision Medicine Inc., a precision oncology company revolutionizing cancer therapies by pre-testing drugs on patient-derived 3D cultures, and Oncodesign (ALONC – FR0011766229), a French biopharmaceutical company specialized in precision medicine, have announced the signature of a research collaboration agreement for R&D of a new personalized cancer treatment for aggressive and untreatable tumors.
DIJON, France & PANGYO, South Korea--(BUSINESS WIRE)--Regulatory News: Oncodesign (ALONC – FR0011766229), a French biopharmaceutical company specialized in kinase inhibitor research and precision medicine, and TiumBio (KOSDAQ:321550), a company specializing in R&D for rare diseases, have announced the signature of a research collaboration agreement on R&D of potential drug candidates for fibrosis.
ONCODESIGN (Paris:ALONC) (ALONC – FR0011766229), a biopharmaceutical group specialized in precision medicine, is today announcing its first-half 2020 revenue and its cash position at June 30, 2020.
Oncodesign and Hitgen have initiated a worldwide strategic alliance in Integrated Drug Discovery Services for the identification and progression of new chemical entities, spanning from Hit finding up to preparation of the Investigational New Drug filing.